- Home
- MNMD vs BZFDW Comparison
MNMD vs BZFDW Comparison
Compare MNMD & BZFDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- BZFDW
- Stock Information
- Founded
- MNMD 2019
- BZFDW N/A
- Country
- MNMD United States
- BZFDW United States
- Employees
- MNMD 74
- BZFDW 611
- Industry
- MNMD Pharmaceuticals and Biotechnology
- BZFDW Movies/Entertainment
- Sector
- MNMD Health Care
- BZFDW Consumer Discretionary
- Exchange
- MNMD Nasdaq
- BZFDW Nasdaq
- Market Cap
- MNMD 541.7M
- BZFDW N/A
- IPO Year
- MNMD N/A
- BZFDW 2021
- Fundamental
- Price
- MNMD $7.02
- BZFDW $0.07
- Analyst Decision
- MNMD Strong Buy
- BZFDW
- Analyst Count
- MNMD 8
- BZFDW 0
- Target Price
- MNMD $26.29
- BZFDW N/A
- AVG Volume (30 Days)
- MNMD 1.0M
- BZFDW N/A
- Earning Date
- MNMD 08-12-2025
- BZFDW N/A
- Dividend Yield
- MNMD N/A
- BZFDW N/A
- EPS Growth
- MNMD N/A
- BZFDW N/A
- EPS
- MNMD N/A
- BZFDW N/A
- Revenue
- MNMD N/A
- BZFDW N/A
- Revenue This Year
- MNMD N/A
- BZFDW N/A
- Revenue Next Year
- MNMD N/A
- BZFDW N/A
- P/E Ratio
- MNMD N/A
- BZFDW N/A
- Revenue Growth
- MNMD N/A
- BZFDW N/A
- 52 Week Low
- MNMD $4.70
- BZFDW N/A
- 52 Week High
- MNMD $10.44
- BZFDW N/A
- Technical
- Relative Strength Index (RSI)
- MNMD 46.62
- BZFDW N/A
- Support Level
- MNMD $6.64
- BZFDW N/A
- Resistance Level
- MNMD $7.34
- BZFDW N/A
- Average True Range (ATR)
- MNMD 0.45
- BZFDW 0.00
- MACD
- MNMD -0.12
- BZFDW 0.00
- Stochastic Oscillator
- MNMD 19.61
- BZFDW 0.00
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About BZFDW BuzzFeed Inc. Warrant
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.